Hjem › Kronisk lymfatisk leukemi › Illinois
Kliniske studier for Kronisk lymfatisk leukemi i Illinois
17 studier for Kronisk lymfatisk leukemi søker deltakere på steder i Illinois.
Byer i Illinois
- Chicago14 studier
- Evanston4 studier
- Springfield4 studier
- Waukegan4 studier
- Danville3 studier
- Champaign3 studier
- Decatur3 studier
- Charleston3 studier
Offisiell studietekst (engelsk)
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- Illinois CancerCare-Bloomington, Bloomington
- Illinois CancerCare-Canton, Canton
- Illinois CancerCare-Carthage, Carthage
- og 27 flere
RekruttererFase 3
Alder 65 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT07321652Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- OSF Saint Anthony's Health Center, Alton
- Rush-Copley Medical Center, Aurora
- Advocate Outpatient Center - Aurora, Aurora
- og 54 flere
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 40 til 75 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT05334069Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Rush-Copley Medical Center, Aurora
- Northwestern University, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- og 28 flere
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 30. sep. 2026 · NCT04269902A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Northwestern University, Chicago
- Illinois Cancer Specialists (Niles) Usor, Niles
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT06943872A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
- Northwestern University, Chicago
- Midwestern Regional Medical Center, Zion
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT07277231A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- University of Chicago Medical Center, Chicago
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT06973187Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- City of Hope - Chicago, Zion
RekruttererFase 1/2
Alder 12 og eldre · Alle kjønn · Oppdatert 3. sep. 2026 · NCT04588922A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
- The David and Etta Jonas Center for Cellular Therapy, Chicago
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 17. aug. 2026 · NCT06528301ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
- Orchard Healthcare Research, Skokie
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 11. aug. 2026 · NCT07342478A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Northwestern University, Chicago
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 2. jul. 2026 · NCT05131022Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- University of Chicago, Chicago
RekruttererFase 1
Alder 13 og eldre · Alle kjønn · Oppdatert 5. mai 2026 · NCT04771572The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- University of Illinois at Chicago Cancer Center, Chicago
RekruttererFase 1/2
Alder 12 til 95 · Alle kjønn · Oppdatert 15. apr. 2026 · NCT04329728A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Springfield Clinic - First /ID# 270145, Springfield
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 9. apr. 2026 · NCT06428019A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- The University of Chicago Medical Center, Chicago
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 20. mar. 2026 · NCT04830137A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- Northwestern University, Chicago
RekruttererFase 4
Alder 18 og eldre · Alle kjønn · Oppdatert 2. mar. 2026 · NCT06876662A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- Northwestern University, Chicago
RekruttererFase 4
Alder 18 og eldre · Alle kjønn · Oppdatert 2. mar. 2026 · NCT06876649AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- Northwestern Memorial Hospital, Chicago
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 10. des. 2025 · NCT05602363Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.